Past events

From basic research to commercial manufacture, this one meeting covers the whole vaccine value chain where science, government and manufacturers all come together to create ground-breaking progress

The AusBiotech conference has served as the leading international meeting place for the Australian life science community. Biotechnology continues to unlock vast potential for improving human life.

The Festival of Biologics Basel is Europe’s largest biologics event, covering the start-to-finish of the industry in antibody therapies, cell and gene therapies, immunotherapies and biosimilars. Designed for industry experts in pharma and biotech, start-ups, academics, regulators and investors, the Festival of Biologics is the meeting place for the large molecule therapy ecosystem, bringing together 3000+ attendees.

This course offers a clear and structured framework for value pricing to get market access in pharma. It provides an overview of the key concepts, frameworks, and evidence-based approaches to get prices right and access delivered. Whether you are involved directly in pricing or work in a related function, this course will help you build the essential knowledge needed to contribute more effectively to pricing and market access decisions.

As global policies converge and value frameworks evolve, collaboration across borders has never been more critical. Under the theme Access Without Borders: Global Strategies for the Next Era, the Lisbon Forum will bring together global leaders in market access, HEOR, policy, and patient engagement to share insights, challenge conventions, and drive action.

The ISPOR Healthcare Investment Summit 2026 brings together investors, drug developers, policy leaders, and value strategists to learn how products are evaluated, paid for, and adopted in an evolving policy environment. Sessions will highlight real investment challenges, surface practical insights, and strengthen connections between capital and evidence that can inform smarter, more resilient investment decisions.

GetReal® Institute is an independent, multi-stakeholder, non-profit forum that unites partners from across Europe and beyond to advance the use of real-world evidence (RWE) in healthcare decision-making

The London Biotech Show is Europe’s flagship biotechnology event, connecting global leaders across biotech to accelerate innovation, partnerships, and investment shaping the future of healthcare and life sciences.

The World Orphan Drug Congress USA brings together the leading pharmaceutical and biotechnology companies, government and regulators, patient advocates, payers, investors, and solution providers – all who all depend on our event to convene and brainstorm ways to advance.

With over 700 participants attending in 2024, the Conference represents an unrivalled opportunity to network and exchange invaluable insights within the rare disease community. Through collaborative efforts, these discussions culminate in clear policy recommendations that can influence both EU and national policies.

By bringing together people with rare diseased and patient advocates, policy makers, healthcare industry representatives, clinicians, regulators and Member State representatives EURORDIS harnesses the power of this extensive network to shape goal-driven rare disease policies of the future.

Most countries have their own Health Technology Assessment (HTA) body with specific views about which criteria to be used and how the HTA process should be conducted. On top of that, EU-level networks strive for a more efficient use of resources and increased collaboration between all stakeholders involved. In this 1-day course you will learn how companies should optimise processes and criteria in this complex environment.

Real World Evidence (RWE) has become an essential addition to Randomised Controlled Trials (RCTs) to further reduce regulatory, payer, physician and patient uncertainty. Unfortunately, many companies struggle implementing it. The key ingredient to success is a cross-functional organisation where managers have widespread knowledge of the fundamentals and a shared vocabulary. In this course you will learn the fundamentals of RWE so that you can contribute effectively when decisions are made and/or when implementing RWE studies.

Join us in May 2026 for the third annual exclusive gathering of senior level investors, corporate executives, entrepreneurs and start-up leaders from biotech, tech bio, biomedical research, drug discovery and healthcare sectors.

Explore how real-world evidence can inform value, affordability, and access decisions for cell and gene therapies.

Policy makers and payers face mounting pressure to make evidence-based decisions that balance innovation with sustainable access. The healthcare ecosystem, real-world data, health economic models, and clinical outcomes assessments continuously demonstrate their ability to generate high-quality evidence and guide these decisions. Health economics and outcomes research (HEOR) stands at the forefront, providing rigorous data, frameworks, and insights needed to demonstrate value, guide resource allocation, and shape policies that matter.

Stay informed and connected by attending the US Pharma and Biotech Summit 2025. Organized by FT Live in collaboration with Endpoints News, the event will bring together top executives, investors and experts to share powerful insights into the future of life sciences in America and worldwide.

ACCESS Forum brings together Thought Leaders, Executives, and Key Stakeholders across Market and Patient Access several times a year to engage, get smarter, problem-solve and challenge the system.

Biosimilar medicines stand at the crossroads of access, sustainability, and industrial resilience. This year’s Biosimilar Medicines Conference programme will explore how strategic coalitions for change can emerge across value chains, geographies, and stakeholders to unlock the full potential of biosimilar medicines to deliver meaningful impact for patients, health systems and society at large.

ISCT is the global leader focused on pre-clinical and translational aspects of developing cell and gene-based therapeutics, thereby advancing scientific research into innovative treatments for patients. Through strong relationships with global regulatory agencies, academic institutions, and industry partners, ISCT drives the advancement of research into a standard of care.